Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

Sponsor
Ruijin Hospital
Study ID
NCT06765928
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • AML, Adult
  • MDS

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A multicenter, single-arm clinical study of evaluate the efficacy and safety of selinexor combined with venetoclax as maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients.

Key Dates

Start date
Jan 1, 2025
Status verified
Jan 2025
Primary completion
Jan 1, 2026
Completion
Jan 1, 2028

Study Design

Enrollment
73 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental arm
    Post allo-HSCT maintenance with selinexor in combination with venetoclax for intermediate to high-risk MDS/AML

Primary Outcome Measure

Progress-free survival [ Time Frame: through study completion, an average of 2 year ]

Central Contacts

Related Studies